CEO Transition at Stoke Therapeutics Marks New Chapter Stoke Therapeutics announced a leadership overhaul as CEO Dr. Edward Kaye stepped down on March 19, 2025, transitioning to an advisory role. Ian F. Smith, a seasoned biotech executive, has been named interim CEO. This change comes amid promising developments for zorevunersen, their lead drug candidate for Dravet syndrome.123